Economic burden of COVID-19 for employers and employees in the United States

Sell, Heather; Schaible, Kassandra; Gouveia-Pisano, Julie A.; Yehoshua, Alon; Malhotra, Deepa; Di Fusco, Manuela; Cha-Silva, Ashley S.; Andersen, Kathleen M.; Nicholls, Lance; Landi, Suzanne N.; Rolland, Catherine; Judy, Jennifer

doi:10.1080/13696998.2024.2309835

Cited by 2 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Introductionmentioning

confidence: 99%

“…1 The burden of COVID-19 is not limited to the acute phase, as even patients with mild disease can experience symptoms and develop conditions that can last months following infection, including long COVID, and might require comprehensive care. [4][5][6] Due to the emergence of novel SARS-CoV-2 viral variants and the observed impact on vaccine performance, the US Food and Drug Administration (FDA) approved and authorized an updated formulation of COVID-19 mRNA vaccines on September 11, 2023, and an adjuvanted protein formulation on October 3, 2023, that were designed to target the circulating omicron variant XBB.1.5 of SARS-CoV-2. 7 On September 12, 2023, the Advisory Committee on Immunization Practices (ACIP) recommended the 2023-2024 Omicron XBB.1.5-containing COVID-19 vaccines for all individuals 6 months of age and older.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis

Kopel,

Araujo,

Bogdanov

et al. 2024

Preprint

View full text Add to dashboard Cite

Background/Objectives COVID-19 continues to pose a significant burden that impacts public health and the healthcare system as the SARS-CoV-2 virus continues to evolve. Regularly updated vaccines are anticipated to boost waning immunity and provide protection against circulating variants. This study evaluated vaccine effectiveness (VE) of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine, at preventing COVID-19-related hospitalizations and any medically attended COVID-19 in adults ≥18 years, overall, and by age and underlying medical conditions. Methods This retrospective cohort study used the Veradigm Network EHR linked to claims data to identify US adults ≥18 years of age who received the mRNA-1273.815 vaccine (exposed) matched 1:1 to individuals who did not receive a 2023-2024 updated COVID-19 vaccine (unexposed). Patients in the unexposed cohort were randomly matched to eligible mRNA-1273.815 recipients. Inverse probability of treatment weighting was used to adjust for differences between the two cohorts. The exposed cohort was vaccinated between September 12, 2023, and December 15, 2023, and individuals in both cohorts were followed up for COVID-19-related hospitalizations and medically attended COVID-19 until December 31, 2023. A Cox regression model was used to estimate the hazard ratio (HR). VE of the mRNA-1273.815 vaccine in preventing COVID-19-related hospitalizations and any medically attended COVID-19 was estimated as 100*(1-HR). Subgroup analyses were performed for adults ≥50, adults ≥65, and individuals with underlying medical conditions associated with severe COVID-19 outcomes. Results Overall, 859,335 matched pairs of mRNA-1273.815 recipients and unexposed adults were identified. The mean age was 63 years, and 80% of the study population was ≥50 years old. 61.5% of the mRNA-1273.815 cohort and 66.4% of the unexposed cohort had an underlying medical condition. Among the overall adult population (≥18 years), VE was 60.2% (53.4-66.0%) against COVID-19-related hospitalization and 33.1% (30.2%-35.9%) against medically attended COVID-19 over a median follow-up of 63 (IQR: 44-78) days. VE estimates by age and underlying medical conditions were similar. Conclusions These results demonstrate the significant protection provided by mRNA-1273.815 against COVID-19-related hospitalizations and any medically attended COVID-19 in adults 18 years and older, regardless of their vaccination history, and support CDC recommendations for vaccination with the 2023-2024 Omicron XBB.1.5-containing COVID-19 vaccine to prevent COVID-19-related outcomes, including hospitalizations.

show abstract

Section: Introductionmentioning

confidence: 99%